Four levels of value judgments in the medical outcome assessment - A systematic approach to the analysis of implicit normativity in evidence based medicine;Vier ebenen von werturteilen in der medizinischen nutzenevaluation eine systematik zur impliziten normativität in der evidenz-basierten medizin

Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung

Volumn 101, Issue 7, 2007, Pages 473-480

  Strech, Daniel ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cost benefit analysis; Critical appraisal; Effectiveness analysis; Evidence based Medicine (EbM); Medical ethics; Transparency; Value judgments

Indexed keywords

EID: 36549074497     PISSN: 14317621     EISSN: 16180992     Source Type: Journal    
DOI: 10.1016/j.zgesun.2007.08.005     Document Type: Article

References (31)

1. Raspe H. Ethische Implikationen der evidenz-basierten Medizin. DMW 2002;127:1769-73.
2. Biller-Andorno N, Lenk C. Ethische Aspekte der Evidenz-basierten klinischen Medizin. ZaeFQ 2003;97:681-7.
3. Ter Meulen R, Biller-Andorno N, Lenk C, Lie RK, Ed. Evidence-based Practice in Medicine & Health Care. A Discussion of the Ethical Issues. Berlin: Heidelberg, Springer; 2005.
4. Goodman KW. Ethics and Evidence-Based Medicine. Fallibility and Responsibility in Clinical Science. New York: Cambridge University Press; 2003.
5. Wiesing U. Wer heilt, hat Recht? Stuttgart, Schattauer; 2004.
6. Moher D, Schulz KF, Altman DG, for the Consort Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-62.
7. Higgins JPT, Green S, Ed. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3. Chichester, UK, John Wiley & Sons, Ltd; 2005.
8. Sackett DL, Straus S, Scott Richardson W. Evidence-Based Medicine. How to Practice Teach EBM. Churchill Livingstone; 2000.
9. Kunz R, Ollenschläger G, Raspe H, et al. Ed. (2007). Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis. Köln, Deutscher Ärzte-Verlag.
10. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. Oxford: Oxford University Press; 2001.
11. Quante M, Vieth A, Welche Prinzipien braucht die Medizinethik? Zum Ansatz von Beauchamp und Childress. Bioethik. Eine Einführung. In: Düwell M, Steigleder K, Frankfurt aM, Suhrkamp; 2003.
12. Noichl F. Neue Rationalität in der Medizin. Ethische Aspekte der Evidence-based Medicine (EBM). Ethica 2001;9:353-74.
13. Fabris F, Scarafiotti C, Maero B. Are Particular Patients Disadvantaged by EBM? Focus on Frail Elderly Patients. Evidence-based Practice in Medicine & Health Care. In: Ter Meulen R, Biller-Andorno N, Lenk C, Lie RK, editors. A Discussion of the Ethical Issues. Berlin: Heidelberg, Springer; 2005. p. 61-4.
14. Rogers WA. Evidence-based Medicine and Equity: the Exclusion of Disadvantaged Groups. In: Ter Meulen R, Biller-Andorno N, Lenk C, Lie RK, editors. Evidence-based Practice in Medicine & Health Care. Berlin: Heidelberg, Springer; 2005. p. 129-38.
15. Reis A, Lenk C, Reis-Streussnig C, Biller-Andorno N. Evidence-based Medicine in Mental Health: towards Better and Fairer Treatment? Evidence-based Practice in Medicine & Health Care. In: Ter Meulen R, Biller-Andorno N, Lenk C, Lie RK, editors. A Discussion of the Ethical Issues. Berlin: Heidelberg, Springer; 2005. p. 65-76.
16. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312(7023):71-2.
17. Birnbacher D. Analytische Einführung in die Ethik. Berlin: Walter de Gruyter; 2003.
18. Kim SYH, Karlawish JHT, Caine ED. Current state of research on decision-making competence of cognitively impaired elderly persons. American Journal of Geriatrics and Psychiatry 2002;10:151-65.
19. Schölmerich P, Thews G. "Lebensqualität" als Bewertungskriterium in der Medizin. New York: Stuttgart; 1990.
20. Goodman SN. The Mammography Dilemma: a Crisis for Evidence-Based Medicine? Ann Intern Med 2002;137:363-5.
21. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:347-60.
22. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355(9198):129-34.
23. NICE, National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: NICE; 2001.
24. Riepe MW, Frölich L, Gertz HJ, et al. Evidenzbasierte medikamentöse Therapie der Alzheimer-Erkrankung. Deutsches Ärzteblatt 2005;102:3587-93.
25. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003.
26. Birks JS, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000.
27. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2002.
28. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, Van Den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Bmj 2005;331(7512):321-7.
29. Molewijk AC, Stiggelbout AM, Otten W, Dupuis HM, Kievit J. Implicit Normativity in Evidence-Based Medicine: a Plea for Integrated Empirical Ethics Research. Health Care Analysis 2003; 11:69-92.
30. Grunwald A. The normative basis of (health) technology assessment and the role of ethical expertise. Poiesis Prax 2004;2:175-93.
31. Reuzel R, Oortwijn W, Decker M, et al. Ethics and HTA: some lessons and challenges for the future. Poiesis Prax 2004;2:247-56.